Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16B |
| 2 |
Bank of America
BAC
|
+$855M |
| 3 |
Comcast
CMCSA
|
+$620M |
| 4 |
Amazon
AMZN
|
+$505M |
| 5 |
Micron Technology
MU
|
+$486M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$441M |
| 2 |
Palo Alto Networks
PANW
|
+$300M |
| 3 |
Verizon
VZ
|
+$286M |
| 4 |
Fidelity National Information Services
FIS
|
+$285M |
| 5 |
Stanley Black & Decker
SWK
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Financials | 6.16% |
| 3 | Industrials | 5.09% |
| 4 | Consumer Discretionary | 4.89% |
| 5 | Healthcare | 4.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3476
AngioDynamics
ANGO
$655M
| $2M | ﹤0.01% |
120,271
+32,034
| +36% | +$547K |
|
3477
Vanda Pharmaceuticals
VNDA
$316M
| $2M | ﹤0.01% |
131,600
-658,785
| -83% | -$9.78M |
|
3478
PUT
International Flavors & Fragrances
IFF
$21.5B
| $2M | ﹤0.01% |
13,100
+2,900
| +28% | +$436K |
|
3479
NeoGenomics
NEO
$2.05B
| $2M | ﹤0.01% |
225,454
+15,934
| +8% | +$147K |
|
3480
PUT
WIX.com
WIX
$3.1B
| $2M | ﹤0.01% |
34,700
+11,200
| +48% | +$693K |
|
|
GHL
3481
DELISTED
Greenhill & Co., Inc.
GHL
| $2M | ﹤0.01% |
102,405
+81,650
| +393% | +$1.52M |
|
3482
PUT
Icon
ICLR
$12.6B
| $2M | ﹤0.01% |
17,800
+12,000
| +207% | +$1.38M |
|
3483
CALL
WEC Energy
WEC
$36B
| $1.99M | ﹤0.01% |
30,000
+25,100
| +512% | +$1.68M |
|
|
OPB
3484
DELISTED
Opus Bank Common Stock
OPB
| $1.99M | ﹤0.01% |
72,908
-44,363
| -38% | -$1.15M |
|
|
BIVV
3485
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $1.99M | ﹤0.01% |
36,907
-88,272
| -71% | -$4.83M |
|
|
RDFN
3486
PUT
DELISTED
Redfin
RDFN
| $1.99M | ﹤0.01% |
63,400
+43,800
| +223% | +$1.06M |
|
3487
Interface
TILE
$2.19B
| $1.99M | ﹤0.01% |
78,964
+42,063
| +114% | +$986K |
|
3488
CALL
Invesco DB Commodity Index Tracking Fund
DBC
$1.73B
| $1.99M | ﹤0.01% |
119,500
+82,900
| +227% | +$1.32M |
|
|
WRK
3489
PUT
DELISTED
WestRock Company
WRK
| $1.99M | ﹤0.01% |
31,400
+500
| +2% | +$30.4K |
|
|
JO
3490
DELISTED
iPath Bloomberg Coffee Subindex Total Return ETN due June 24, 2038
JO
| $1.98M | ﹤0.01% |
126,364
+114,711
| +984% | +$1.83M |
|
3491
Xcel Energy
XEL
$49.5B
| $1.98M | ﹤0.01% |
41,200
-49,732
| -55% | -$2.47M |
|
|
CEO
3492
CALL
DELISTED
CNOOC Limited
CEO
| $1.98M | ﹤0.01% |
13,800
-100
| -0.7% | -$13.6K |
|
3493
ProShares UltraShort Yen
YCS
$30M
| $1.98M | ﹤0.01% |
105,580
+50,936
| +93% | +$954K |
|
|
QVCGA
3494
PUT
DELISTED
QVC Group Inc Series A
QVCGA
| $1.98M | ﹤0.01% |
1,669
+1,232
| +282% | +$1.43M |
|
|
WUBA
3495
DELISTED
58.com Inc
WUBA
| $1.98M | ﹤0.01% |
+27,620
| New | +$1.91M |
|
3496
CALL
Franklin Resources
BEN
$17.2B
| $1.98M | ﹤0.01% |
45,600
-23,800
| -34% | -$1.03M |
|
3497
CALL
GoPro
GPRO
$110M
| $1.98M | ﹤0.01% |
261,000
+3,700
| +1% | +$32.8K |
|
|
HTT
3498
High Templar Tech Ltd
HTT
$393M
| $1.98M | ﹤0.01% |
+157,549
| New | +$3.04M |
|
3499
Sanofi
SNY
$105B
| $1.98M | ﹤0.01% |
+45,957
| New | +$2.12M |
|
3500
EXL Service
EXLS
$5.28B
| $1.97M | ﹤0.01% |
163,435
+59,560
| +57% | +$727K |
|
Similar funds
Ken Griffin's Q4 2017 Portfolio in Review
As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.
- Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
- Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
- Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
- Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
- Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.